Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $57.83
  • 50 Day Moving Average: $30.90
  • 200 Day Moving Average: $22.21
  • 52-Week Range: $47,899,000.00 - $8.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -25.59
  • P/E Growth: 69.35
  • Market Cap: $2.77B
  • Outstanding Shares: 47,899,000
  • Beta: 1.61
  • Return on Equity: -157.82%
  • Return on Assets: -106.30%
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 2.91%
  • Quick Ratio: 2.91%
Additional Links:
Companies Related to Sarepta Therapeutics:

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $51.76 (10.49% downside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetDetails
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00View Rating Details
9/20/2016Needham & Company LLCBoost Price TargetBuy$47.00 -> $81.00View Rating Details
9/20/2016WedbushReiterated RatingOutperform$66.00View Rating Details
9/20/2016Cowen and CompanyUpgradeMarket Perform -> Outperform$64.00View Rating Details
9/19/2016Oppenheimer Holdings Inc.Boost Price Target$60.00 -> $76.00View Rating Details
9/19/2016JMP SecuritiesUpgradeOutperform$10.00 -> $60.00View Rating Details
9/19/2016Jefferies GroupUpgradeUnderperform -> Hold$50.00View Rating Details
9/19/2016RBC Capital MarketsUpgradeSector Perform -> OutperformView Rating Details
9/19/2016Leerink SwannUpgradeUnderperform -> Market Perform$50.00View Rating Details
9/19/2016Royal Bank Of CanadaUpgradeSector Perform -> Outperform$83.00View Rating Details
9/19/2016Piper Jaffray Cos.UpgradeNeutral -> OverweightView Rating Details
9/19/2016William BlairUpgradeMarket Perform -> Outperform$88.00View Rating Details
9/19/2016Janney Montgomery ScottUpgradeNeutral -> Buy$30.00 -> $65.00View Rating Details
9/14/2016SunTrust Banks Inc.UpgradeReduce -> NeutralView Rating Details
7/18/2016Robert W. BairdReiterated RatingOutperform$23.00View Rating Details
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details
10/23/2015Bank of America Corp.Initiated CoverageBuy$49.00View Rating Details
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details
5/23/2015Deutsche Bank AGReiterated RatingHold$24.00View Rating Details
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details
10/7/2014Credit Suisse Group AGReiterated RatingOutperformView Rating Details
(Data available from 9/26/2014 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q2($1.19)($1.35)ViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
Current Year EPS Consensus Estimate: $-5.14 EPS
Next Year EPS Consensus Estimate: $-2.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.38)($0.59)($1.09)
Q4 20166($1.22)($0.47)($0.86)
Q1 20171($0.80)($0.80)($0.80)
Q2 20171($0.85)($0.85)($0.85)
Q3 20171($0.78)($0.78)($0.78)
Q4 20171($0.84)($0.84)($0.84)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 72.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline logoFor Traders, Planning Is More Important Than the Plan (NASDAQ:SRPT) - September 25 at 11:58 AM logoThe Woman Behind Sarepta Therapeutics' Success (NASDAQ:SRPT) - September 24 at 8:31 AM logoSarepta Therapeutics : Group One Trading buys $14,427,123 stake in Sarepta Therapeutics Inc (SRPT) (NASDAQ:SRPT) - September 23 at 6:51 PM logoSAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St (NASDAQ:SRPT) - September 23 at 6:51 PM logoSarepta: Look For Lift Post Impressive Secondary Price (NASDAQ:SRPT) - September 23 at 11:29 AM logoSizzling Sarepta Therapeutics Inc (SRPT) Targeted by Option Bulls (NASDAQ:SRPT) - September 23 at 11:29 AM logoCompany Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Pricing of $300 Million Public Offering of Common Stock (NASDAQ:SRPT) - September 23 at 11:29 AM logo2:40 am Sarepta Therapeutics prices 5.02 mln shares of its common stock at $59.75 per share (NASDAQ:SRPT) - September 23 at 11:29 AM logoSizzling Sarepta Therapeutics Inc (SRPT) Targeted by Option Bulls - Schaeffers Research (blog) (NASDAQ:SRPT) - September 22 at 7:06 PM logoSarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (NASDAQ:SRPT) - September 22 at 7:06 PM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Trading Up – Insider Trading Activity (NASDAQ:SRPT) - September 22 at 11:37 AM logoSarepta Therapeutics Inc (SRPT) Shares Rise Amid $225 Million Stock Offering (NASDAQ:SRPT) - September 22 at 11:37 AM logoHow Sarepta Is Cashing In on Its FDA Homerun (NASDAQ:SRPT) - September 22 at 11:37 AM logoI Am One of the Underinvested Bulls Right Now (NASDAQ:SRPT) - September 22 at 11:37 AM
News IconSarepta to Sell Up to $225 Million of Stock (NASDAQ:SRPT) - September 21 at 6:59 PM logoWilliam Blair Weighs in on Sarepta Therapeutics Inc (SRPT) Following Favorable Decision in Patent Appeal (NASDAQ:SRPT) - September 21 at 6:59 PM logoSarepta Therapeutics Announces Proposed Public Offering of Common Stock (NASDAQ:SRPT) - September 21 at 6:59 PM logo[$$] Sarepta to Sell Up to $225 Million of Stock (NASDAQ:SRPT) - September 21 at 6:59 PM logoBRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock (NASDAQ:SRPT) - September 21 at 4:58 PM logoSarepta Therapeutics (SRPT) Appoints Edward Kaye as Permanent CEO; Updates on Exec Team - (NASDAQ:SRPT) - September 21 at 11:34 AM logoCompany Update (NASDAQ:SRPT): Sarepta Therapeutics Inc ... - Smarter Analyst (NASDAQ:SRPT) - September 21 at 11:34 AM logoAnalysts Dive in on Two Volatile Biotech Stocks: Sarepta Therapeutics Inc (SRPT), Vical Incorporated (VICL) - Smarter Analyst (NASDAQ:SRPT) - September 21 at 11:34 AM logoForget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy (NASDAQ:SRPT) - September 20 at 4:19 PM logoHere's Why Sarepta Therapeutics, Inc's Stock is Jumping Again (NASDAQ:SRPT) - September 20 at 1:13 PM
News IconSarepta Therapeutics Inc (NASDAQ:SRPT) & Finisar Corporation (NASDAQ:FNSR) UPDATE ON U.S STOCKS : 19 ... - Money News (NASDAQ:SRPT) - September 20 at 11:12 AM logoAnalyst Upgrades: Sarepta Therapeutics Inc, Cirrus Logic, Inc., and Advanced Micro Devices, Inc. - Schaeffers Research (blog) (NASDAQ:SRPT) - September 20 at 11:12 AM logoPuma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA (NASDAQ:SRPT) - September 20 at 11:12 AM logoSarepta Stock Nearly Doubles on FDA Approval for DMD Drug (NASDAQ:SRPT) - September 20 at 11:12 AM logoCompany News for September 20, 2016 (NASDAQ:SRPT) - September 20 at 11:12 AM logoSarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target? (NASDAQ:SRPT) - September 20 at 11:12 AM logoThe Market In 5 Minutes: Traders In A Standstill Ahead Of FOMC Meeting (NASDAQ:SRPT) - September 20 at 9:24 AM
News IconSarepta Therapeutics Inc (NASDAQ:SRPT): Our Subecribers Bought The Stock At $28 And Now Up 85% Quickly (NASDAQ:SRPT) - September 19 at 7:23 PM logoHere’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT) (NASDAQ:SRPT) - September 19 at 7:23 PM logoNotable Analyst Price Target Changes: Sarepta Therapeutics Inc (SRPT), GoPro Inc (GPRO) (NASDAQ:SRPT) - September 19 at 7:23 PM logoCramer Remix: Another speculative biotech with tremendous upside (NASDAQ:SRPT) - September 19 at 7:23 PM logoWhy Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks (NASDAQ:SRPT) - September 19 at 5:31 PM logoMid-Day Market Update: Crude Oil Up 2%; Sarepta Therapeutics Shares Spike Higher (NASDAQ:SRPT) - September 19 at 12:47 PM logoMost Active Weekly Options: Sarepta Therapeutics Inc and Chesapeake Energy Corporation - Schaeffers Research (blog) (NASDAQ:SRPT) - September 19 at 11:58 AM logoFDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen - (NASDAQ:SRPT) - September 19 at 11:58 AM logoSarepta Stock Soars On FDA OK For Muscular Dystrophy Drug (NASDAQ:SRPT) - September 19 at 11:58 AM logoSarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch (NASDAQ:SRPT) - September 19 at 11:58 AM logo​FDA grants accelerated approval to Sarepta’s Duchenne drug (NASDAQ:SRPT) - September 19 at 11:58 AM logoSarepta Therapeutics Inc (SRPT), PTC Therapeutics, Inc. (PTCT) and More: Here’s Why These Stocks Are on Investors’ Radars Today (NASDAQ:SRPT) - September 19 at 11:58 AM logo[$$] FDA Approves Sarepta's Dystrophy Drug (NASDAQ:SRPT) - September 19 at 11:58 AM logoHere’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT) (NASDAQ:SRPT) - September 19 at 11:40 AM logoSarepta shares briefly leap 80% after FDA approves drug (NASDAQ:SRPT) - September 19 at 11:00 AM logoBRIEF-U.S. FDA grants accelerated approval to Sarepta Therapeutics' Duchenne Muscular Dystrophy drug (NASDAQ:SRPT) - September 19 at 10:39 AM logoSarepta Therapeutics Inc (NASDAQ:SRPT): Jefferies Says Chances for Eteplirsen’s Approval Are Still Slim (NASDAQ:SRPT) - September 18 at 11:36 AM
News IconBank of America Corp (NYSE:BAC) & Sarepta Therapeutics Inc ... - Money News (NASDAQ:SRPT) - September 16 at 7:08 PM
News IconBiotech Stocks Worth a Closer Look: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Sarepta Therapeutics, Inc ... - The Voice Registrar (NASDAQ:SRPT) - September 16 at 7:08 PM


Sarepta Therapeutics (NASDAQ:SRPT) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff